ARWR (Arrowhead Pharmaceuticals, Inc.) Quarterly EPS earnings growth

Arrowhead Corp (ARWR) - corporate logo

The quarterly EPS growth snapshot demonstrates profitability dynamics, where -1628.20 expresses the current value of the metric for Arrowhead Pharmaceuticals (ARWR). The delivery of RNA drugs requires costly temperature control to preserve their properties. Meanwhile, the TRiM platform provides significant pricing power due to its unique impact on genes. Arrowhead Pharmaceuticals (ARWR) is currently preparing to scale, although massive R&D expenditures are keeping net income low.

arrowheadpharma.com (ARWR) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/15/2026

arrowheadpharma.com (ARWR) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Summary company analytics:Arrowhead Pharmaceuticals
Manufactured product of Arrowhead Pharmaceuticals

Quarterly EPS growth measures the percentage change in net income per share, reflecting the efficiency of business capitalization. Professionals utilize this rate to assess profit scalability and market consensus. By analyzing the quarterly EPS chart, an investor can see the current value of -1628.20. This indicator is critical for Arrowhead Pharmaceuticals (ARWR), as its growth will be driven by the successful market launch of RNAi drugs for respiratory and liver therapies.